Where are we on SCUBE3? Have they even started clinical trials? Chat 9/5/2023
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity New drug for hair loss announced by Amplifica
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
community I am a dermatologist with a clinical interest in alopecia. AMA
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Any treatments in development that could theoretically give complete regrowth?
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
community A New Hair Loss Drug Could Cure Balding and Reverse Graying
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
Related Research
6 / 6 results
research Stem Cell Applications in Human Hair Growth: A Literature Review
This review explores stem cell applications for hair regrowth in alopecia, with no new clinical results, suggesting potential advantages over current FDA-approved treatments.
research Rhamnose-mediated modulation of hair follicle growth: insights from chemical genomics
This study found that rhamnose can restore hair-inducing gene expression in dermal papilla cells and accelerate hair follicle regeneration by promoting the hair cycle into the anagen phase, suggesting its potential therapeutic application for alopecia treatment.
research Progress on mitochondria and hair follicle development in androgenetic alopecia: relationships and therapeutic perspectives
This review highlights the critical role of mitochondrial dysfunction in hair loss, particularly androgenetic alopecia, and explores potential therapies targeting mitochondrial pathways to improve hair health, underscoring the need for further research in this area.
research Exploring the Complexities of TGF-beta Signaling in Keloids: Beyond the Classical Smad Pathway
This study reviews evidence that in keloid development, transforming growth factor-β (TGF-β) drives fibroblast proliferation and fibrosis not only through the classical Smad-dependent pathway but also via equally important Smad-independent signaling cascades, suggesting these pathways as possible targets for more effective keloid therapies.
research Signal Peptide-CUB-EGF-like Domain-Containing Protein 3 (SCUBE3): From Molecule to Therapy
This study found that SCUBE3 protein is upregulated in various cancers, promoting tumor growth and poor outcomes, while suppressing growth in renal cell carcinoma, and may serve as a diagnostic marker and potential therapeutic target for several diseases due to its secreted nature.
research Characterization of a mouse Scube3 reporter line
Mouse Scube3 affects teeth, tongue, vibrissae, and eye development, but not facial structure or limb growth.